Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Paclitaxel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 3/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 3/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 3/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 3/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 3/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 3/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 3/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 3/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 3/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 3/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 3/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 3/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 3/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 3/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paclitaxel SCHEMBL1560990 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL788187 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL14580645 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760447 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL18997 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760443 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL13174850 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL17897671 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL22149786 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL177944 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308270-A1 | SYSTEMS AND METHODS FOR INTRACELLULAR DELIVERY VIA NON-CHARGED SEQUENCE-DEFINED CELL-PENETRATING OLIGOMERS | CORNELL UNIVERSITY | 2021-10-07 | — | — | US | disclosed |
| US-10610565-B2 | Prevention and treatment of ocular side effects with a cyclosporin | ALLERGAN, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-9839667-B2 | Prevention and treatment of ocular side effects with a cyclosporin | ALLERGAN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-8138361-B2 | C-10 carbamates of taxanes | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090306014-A1 | C-10 CARBAMATES OF TAXANES | ACIDOPHIL LLC (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308270-A1 | SYSTEMS AND METHODS FOR INTRACELLULAR DELIVERY VIA NON-CHARGED SEQUENCE-DEFINED CELL-PENETRATING OLIGOMERS | TLR3, HSPE1, GLS | TUBB4A 467/4885TUBB 188/4885TUBA3C 541/4885 |
| US-20090306014-A1 | C-10 CARBAMATES OF TAXANES | CASP10, S100A10, ATXN10 | TUBB4A 46/4885TUBB 29/4885TUBA3C 18/4885 |
| US-10610565-B2 | Prevention and treatment of ocular side effects with a cyclosporin | CTSA, CHP1, EYA3 | TUBB4A 296/4885TUBB 147/4885TUBA3C 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.